Development of immune checkpoint inhibitors for treating various cancer diseased conditions

Abstract

Cancer is a state which involves an abnormal increase in the number of cells, with a potentiality to invade or spread to other parts of the body and destroy their function. Every individual is born with an immune system that acts as a security checkpoint. The immune system does possess B and T lymphocytes, B -cells acts as the military intelligence and T-cells acts as soldiers it also possesses some receptors that scan normal cells and abnormal cells like a virus and some other cells. Abnormal cells are detected and removed by the T-cells, but in some conditions, T-cells fail to detect and eliminate cancer cells. This is because of higher mutations in cancer cells leads to a development of some of the receptors like PD-L1 which acts as the signal jammer of the T-cell. This leads to failure in the work of T-cells against the cancer cells not only this some other receptors like CTLA-4 of T-Cells acts as a type of “off switch” to keep the immune system in off. Immune checkpoint inhibitors are used by targeting PD-1, PD-L1 and CTLA-4 targets and drugs like pembrolizumab, nivolumab, ipilimumab and etc. are used to treat various types of cancer.

Authors and Affiliations

Ramoju Kishore Kumar

Keywords

Related Articles

Evaluation of antipyretic activity of leaf extracts of Triumfetta rhomboidea Jacq

A study was carried out to evaluate the anti-pyretic potential of the ethanol extract of Triumfetta rhomboidea leaves using Yeast induced pyrexia in wister albino rats. Rectal temperatures were recorded before and after...

A prevalence of common risk factors of hypertension among young generation living in Dhaka city: a cross-sectional study

Hypertension is one of the upward health related challenge in Bangladesh and hypertension in young generation is increasing but there is a shortage of data about the risk factors in this age group. The aim was to evaluat...

An observative study of comparison of efficacy and tolerability between amolodopine and atenolol in the maintence therapy of hypertension in a tertiary care hospital

Background Hypertension is the most common cardiovascular disease. The prevalence of hypertension increases with advancing age. The beta receptor antagonists provide effective therapy for all grades of hypertension. Com...

Invitro alpha amylase effect of Sida acuta Burm

Introduction Sida acuta is shrub indigenous to pantropical areas, widely distributed in regions and found in pastures, waste lands, cultivated lands, roadsides, lawns and planted forests. Sida acuta is ethanomedically us...

Consideration of ethnic factors during drug approval process

Purpose To determine feasibility of drug registration for the selected drugs at USFDA based on the ICH E5 guideline. Methods Methodology involves two steps, they are 1. Determination of ethnic sensitivity of the selected...

Download PDF file
  • EP ID EP540437
  • DOI -
  • Views 146
  • Downloads 0

How To Cite

Ramoju Kishore Kumar (2017). Development of immune checkpoint inhibitors for treating various cancer diseased conditions. International Journal of Pharmacology and Clinical Research (IJPCR), 1(2), 19-24. https://europub.co.uk/articles/-A-540437